Skip to Content

Motavizumab Approval Status

Motavizumab is an investigational monoclonal antibody (MAb) for the prevention of serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.

In September 2010, MedImmune, Inc. announced the receipt of a second Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for motavizumab had not been approved.

Development Status and FDA Approval Process for motavizumab

Sep  7, 2010Medimmune Receives Complete Response Letter On Motavizumab
Jun  3, 2010FDA Advisory Committee Reviews MedImmune's Motavizumab
Dec  1, 2008MedImmune Receives FDA Complete Response Letter on Motavizumab
Feb  4, 2008MedImmune Submits Biologics License Application to FDA for Motavizumab

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.